Laser zaps NF1 skin bumps in small trial
NCT ID NCT06934928
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether monthly alexandrite laser treatments can safely shrink or improve the look of skin tumors in adults with neurofibromatosis type 1 (NF1). Ten participants will receive up to six monthly laser sessions, with some areas treated with cooling and others without. The main goals are to check for side effects and see if tumors shrink by more than half.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Alexandrite laser (755 nm) with skin cooling
- What this could lead to
- If it works, this could offer a non-surgical option to shrink or improve the appearance of skin tumors in people with NF1.
- What could go wrong
- This is a very small, early-stage trial (10 people) that is currently suspended. It only tests safety and tumor appearance, not long-term outcomes. Skin reactions or pain may occur.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 10 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jan 2027
An estimate. Start dates often move.
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Participant is an adult ≥18 years of age. * Participant has a diagnosis of NF1 based on germline genetic testing or by meeting ≥ 2 the following criteria: * Family history of NF1 * Six or more light brown ("cafe-au-lait") spots on the skin * Presence of two or more neurofibromas of any type, or one or more plexiform neurofibromas * Freckling under the arms or in the groin area * Two or more pigmented, benign bumps on the eye's iris (Lisch nodules) * A distinctive bony lesion: dysplasia (abnormal growth) of the sphenoid bone behind the eye, or dysplasia of long bones, often in the lower leg * Tumor on the optic nerve that may interfere with vision * Participant is seeking treatment for cNF. * Participants must have ≥ 12 paired cNF (6 to be treated without DCD, 6 to be treated with DCD) that are visible and measure at least 2 mm in size in the target treatment area. The target treatment area must be amenable to both laser treatments and surveillance with digital and 3D photography. Preferred locations are trunk (back or chest), arms and legs. * Participant is able and willing to comply with all visit, treatment, and evaluation schedules and requirements. * Participant is able to understand and provide written informed consent. * Participant has no concurrent injury or wound in the target area. Exclusion Criteria: * Participant cannot give informed consent or adhere to study schedule. * Participant is Fitzpatrick skin type V-VI. * Participant is actively tanning during the course of the study. * For female participants: participant is pregnant. * Participant has any condition which, in the Investigator's opinion, would make it unsafe (for the participant or study personnel) to treat the participant as part of this research study.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Neurofibromatosis 1 (NF1) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Wellman Center for Photomedicine, Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.